Pisoni CN et al. J Rheumatol 2005; 32:1047-1052
2
Pisoni CN et al. J Rheumatol 2005; 32:1047-1052 Measure Baseline After treatment p Average steroid dose (mg/d) 17.95 10.86 <0.0001 ESR (mm/h) 38.2 29.19 0.003 Anti-dsDNA (IU/mL) 47.41 30.3 0.004 ECLAM 3.83 2.49 <0.0001 Complement C3 (g/L) 0.66 0.84 <0.0001 Effects of MMF treatment in patients with SLE
-
Upload
wynter-mueller -
Category
Documents
-
view
23 -
download
2
description
Effects of MMF treatment in patients with SLE. Pisoni CN et al. J Rheumatol 2005; 32:1047-1052. Effects of MMF treatment in patients with lupus nephritis. Pisoni CN et al. J Rheumatol 2005; 32:1047-1052. - PowerPoint PPT Presentation
Transcript of Pisoni CN et al. J Rheumatol 2005; 32:1047-1052
Pisoni CN et al. J Rheumatol 2005;32:1047-1052
Measure Baseline After treatment p
Average steroiddose (mg/d)
17.95 10.86 <0.0001
ESR (mm/h) 38.2 29.19 0.003 Anti-dsDNA (IU/mL) 47.41 30.3 0.004 ECLAM 3.83 2.49 <0.0001 Complement C3 (g/L) 0.66 0.84 <0.0001
Effects of MMF treatment in patients with SLE
Pisoni CN et al. J Rheumatol 2005;32:1047-1052
Measure Baseline After treatment p
Average steroiddose (mg/d)
17.71 9.38 <0.0001
24-h proteinuria(g/24 h)
3.01 1.85 0.001
Effects of MMF treatment in patients with lupus nephritis
